An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Status: Enrolling by Invitation

Description

The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.

Eligibility Criteria

Inclusion Criteria

  • Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.
  • Currently tolerating treatment in the parent protocol.
  • Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.
  • Have at least stable disease, as determined by the investigator.
  • Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.

Exclusion Criteria

  • Has been permanently discontinued from study treatment in the parent study for any reason.
  • Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.

Locations & Contacts

California

Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: Active
Name Not Available

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
Incyte Corporation

Trial IDs

Primary ID INCB 18424-270
Secondary IDs NCI-2017-00377
Clinicaltrials.gov ID NCT02955940